Every ad on this page had an insertion in 2020 unless stated otherwise.
Marginal ads are falling by the wayside faster in late 2020.
Likely, the sharp drop in newsstand and retail point of sale of newspapers has knocked weaker products and poorer performing ads out of the market.
The STAR rating assigned to each ad reflects the number of insertions, as accurately as can be ascertained by the listed number of results in the archive.
For example, the results for Urivarx in 2020 are below. The actual number of insertions is something like ten fold what the archive shows.
Urivarx remains one of the blockbusters in its space and so it’s assigned a 4.5 out of 5
By comparison, here are the results for TruDNA during 2020.
The advertiser seems to have stopped running the ad in early March which would seem to suggest it was marginally successful and they pulled the plug 2-3weeks after the quarantine hit.
Product: AloeCure
Market: Digestion is the core and original market. Anti-aging has been the lead approach since 2019 and it’s positioned as an all-in-one super supplement.
Earliest ad insertion: April 2010
Current: Yes
Stars 5 of 5
AloeCure continues its 10-year evolution and during 2020 is now running with anti-aging first and digestion as a secondary product benefit.
If I had to guess, I’d say AC has reached its high water mark because there’s less of the voracious testing, seen just a few years ago, since they’ve drifted from digestion to anti-aging.
Scientists Target New Acid Reflux Pill for Anti-Aging Research is the winner as of September 2020
Leading Ingredient For Acid Reflux Bouts Linked To Anti-Aging Phenomenon They’ve run this one as a full page when they can get the rates.
This Amazing Acid Reflux Pill Has Really Weird Health Benefits This had a few dozen insertions between 10-19 and 02-20
Leading Acid Reflux Pill Creates Immune System Phenomenon A few dozen insertions in April, but no staying power. This seems to be the norm for many supplement sellers who’ve tried to “cross over” into immune defense.
Product: Urivarx
Market: Incontinence. Urivarx is still killing it in print and the advertiser is sticking with their proven leads, while continuing to vigorously test. Urivarx is definitely on the short list for best selling supplements in print.
Earliest ad insertion: December 2016
Current: Yes
Stars 4.5 of 5
This New Bladder Control Pill May Replace Adult Diapers This one is top dog in late 2020.
Rumors of New Bladder Control Pill Have Adult Diaper Companies in a Panic Ran from October 2019 through December 2019.
Adult Diaper Companies Panic as New Bladder Pill Slashes Pad Use Also running STRONG since October 2019
Adult Diaper Companies Panic as New Bladder Pill Slashes Pad Use This one is a variation of the above which was tested several times. The insertion without the cross-out is the winner.
New Pill Strengthens The Bladder Muscles, Reducing Accidents and Bed Wetting February of 2020 to June of 2020. These guys keep pushing the envelope when it comes to testing.
Product: Diabasens (aka Neuriterx)
Market: Neuropathy
Earliest ad insertion: May 2018
Current: Yes
Stars 4 of 5
Researchers Close in on a Pain Reliever Specific to Nephropathy This version has been running in Canada only during 2020, likely due to compliance.
Tortured by Neuropathy Discomfort? This has been doing well since May of 2019 and is picking up the rate of insertions in September of 2020. They are grabbing full pages for this hot insertion when they can get the rates. The “Neuriterx” name has largely replaced “Diabasens.”